search
Back to results

Seal-G / Seal-G MIST Study

Primary Purpose

Colon Cancer, Gastrointestinal Cancer

Status
Recruiting
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Seal-G Surgical Sealant
Seal-G MIST System
Sponsored by
Advanced Medical Solutions Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Colon Cancer

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subject signs and dates a written ICF, indicates an understanding of the study procedures and follow-up requirements and is willing to comply with them.
  2. Subject is aged 18 years to 80 years
  3. Subject is scheduled for elective open or laparoscopic (including robotic) colon cancer resection surgery with primary anastomosis (excluding low anterior resection)

Exclusion Criteria:

  1. Anastomosis is expected to be ≤ 10cm from anal verge
  2. Surgery involves stoma creation
  3. Subject who underwent a prior pelvic radiation therapy
  4. Subject with a BMI > 40 or <19
  5. Subject with ASA status higher than 3
  6. Albumin level < 3 gr/dl
  7. Total bilirubin >1.5 mg/dL
  8. Hemoglobin level < 8mg/dl on day of surgery
  9. Subject has a diagnosis of bowel strangulation, peritonitis, bowel perforation, local or systemic infection, ischemic bowel, and carcinomatosis
  10. Subject treated with immunosuppressive agents within 28 days prior to study enrollment (including corticosteroids)
  11. Serious or uncontrolled co-existent diseases (e.g. severe cardiovascular disease, congestive heart failure, recent myocardial infarction within 6 months from surgery, significant vascular disease, active or uncontrolled autoimmune disease, active or uncontrolled infection, uncontrolled DM with episodes of hospitalization due to hypo or hyperglycemia within 6 months of surgery)
  12. Subject known to have distant metastases, such as liver, lung, bone etc. metastases (not including local and regional lymph nodes)
  13. Subject with known sensitivity to Indigo carmine dye (FD&C 2/ E132)
  14. Subject who according to the investigator clinical judgement is not suitable for participation in the study or is at risk
  15. Subject requires more than one anastomosis during the surgery
  16. Subject is scheduled for another surgery during the follow up period of this study
  17. Subjects who cannot comply with study visits/ procedures or have poor compliance (e.g. mentally handicapped, prisoners, etc.)

Intraoperative Exclusion Criteria:

Subjects who meet any of the following intra-operative exclusion criteria will be considered as screen failures and will not be eligible for the study:

  1. Positive leak test requires anastomosis takedown and/or re-anastomosis.
  2. Additional resection (not including tissue biopsy) of non-colonic solid organ (e.g. Liver resection, uterus, bladder, seminal vesicle, ureter)
  3. Subjects whom anastomosis is ≤10 cm from the anal verge
  4. Subject received intraoperative sealant, glue or any buttressing material for the study related anastomosis, other than the Seal-G/Seal-G MIST
  5. Subject received two or more units of PC transfusion during surgery
  6. Subject has peritoneal carcinomatosis or any other metastasis observed by the surgeon

Sites / Locations

  • Sheba Medical Center (Tel Hashomer)Recruiting
  • Shamir (Assaf Harofeh) Medical CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Seal G / Seal-G MIST

Arm Description

Seal-G Surgical Sealant [Seal-G]- will be applied on colonic anastomosis created by extra-corporal approach. Seal-G MIST System [Seal-G MIST]- will be applied on colonic anastomosis created by intra-corporal approach.

Outcomes

Primary Outcome Measures

Proportion of surgeries with full sealant coverage - successful application
1- The surgeon applied the sealant over the full circumference of the anastomosis (successful application). 0 - The surgeon did not fully cover the anastomosis circumference

Secondary Outcome Measures

Proportion of subjects with clinical anastomotic leaks
1 - The subject had a clinical anastomotic leak 0 - The subject did not have a clinical anastomotic leak
Proportion of subjects with subclinical / radiological leaks
1 - The subject had a Subclinical /radiological anastomotic leak 0 - The subject did not have a Subclinical /radiological anastomotic leak
Proportion of subjects with at least one Serious Adverse Event
1 - The subject had any Serious adverse event 0 - The subject did not have Serious adverse event
Proportion of subjects that had a reoperation
1 - The subject had any event of reoperation 0 - The subject did not have reoperation
Hospital length of stay
Measured by the time for "Ready to be discharged" (in days)

Full Information

First Posted
August 26, 2020
Last Updated
August 10, 2023
Sponsor
Advanced Medical Solutions Ltd.
Collaborators
ClinSearch, Advanced Medical Solutions Israel (Sealantis) Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04532515
Brief Title
Seal-G / Seal-G MIST Study
Official Title
Seal-G and Seal-G MIST Study for Reinforcement and Protection of Colonic Anastomoses in Subjects Undergoing Colonic Resection
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 1, 2021 (Actual)
Primary Completion Date
July 25, 2023 (Actual)
Study Completion Date
October 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Advanced Medical Solutions Ltd.
Collaborators
ClinSearch, Advanced Medical Solutions Israel (Sealantis) Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A prospective, multi-center, open label, study to evaluate safety and performance of Seal-G and Seal-G MIST in reinforcing colonic anastomosis, in subjects undergoing Colon Resection surgery
Detailed Description
Seal-G and Seal-G MIST Surgical Sealants are intended for the reinforcement and protection of gastrointestinal anastomosis. The Seal-G and Seal-G MIST devices share the same Alginate based sealant technology and intended purpose. The devices only differ in their method of application, The Seal-G device is designed for spread application by extra-corporal approach, and the Seal-G MIST device is designed for spray application by intra-corporal approach. The proposed Clinical Investigation aims to collect clinical evidence on the devices' usage, including safety, performance and usability.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colon Cancer, Gastrointestinal Cancer

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Seal-G Product Family variants will be used as the study device (Treatment) according to the following scheme: Seal-G Surgical Sealant [Seal-G]- will be applied on colonic anastomosis created by extra-corporal approach. Seal-G MIST System [Seal-G MIST]- will be applied on colonic anastomosis created by intra-corporal approach. Intended Use: Seal-G/Seal-G MIST are surgical sealants intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses. Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis
Masking
None (Open Label)
Allocation
N/A
Enrollment
160 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Seal G / Seal-G MIST
Arm Type
Experimental
Arm Description
Seal-G Surgical Sealant [Seal-G]- will be applied on colonic anastomosis created by extra-corporal approach. Seal-G MIST System [Seal-G MIST]- will be applied on colonic anastomosis created by intra-corporal approach.
Intervention Type
Device
Intervention Name(s)
Seal-G Surgical Sealant
Other Intervention Name(s)
Seal-G
Intervention Description
Seal-G is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses. Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis
Intervention Type
Device
Intervention Name(s)
Seal-G MIST System
Other Intervention Name(s)
Seal-G MIST
Intervention Description
Seal-G MIST is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses. Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis
Primary Outcome Measure Information:
Title
Proportion of surgeries with full sealant coverage - successful application
Description
1- The surgeon applied the sealant over the full circumference of the anastomosis (successful application). 0 - The surgeon did not fully cover the anastomosis circumference
Time Frame
At time of surgery
Secondary Outcome Measure Information:
Title
Proportion of subjects with clinical anastomotic leaks
Description
1 - The subject had a clinical anastomotic leak 0 - The subject did not have a clinical anastomotic leak
Time Frame
Up to 30 days post-surgery
Title
Proportion of subjects with subclinical / radiological leaks
Description
1 - The subject had a Subclinical /radiological anastomotic leak 0 - The subject did not have a Subclinical /radiological anastomotic leak
Time Frame
Up to 30 days post-surgery
Title
Proportion of subjects with at least one Serious Adverse Event
Description
1 - The subject had any Serious adverse event 0 - The subject did not have Serious adverse event
Time Frame
Up to 30 days post-surgery
Title
Proportion of subjects that had a reoperation
Description
1 - The subject had any event of reoperation 0 - The subject did not have reoperation
Time Frame
Up to 30 days post-surgery
Title
Hospital length of stay
Description
Measured by the time for "Ready to be discharged" (in days)
Time Frame
Up to 30 days post-surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject signs and dates a written ICF, indicates an understanding of the study procedures and follow-up requirements and is willing to comply with them. Subject is aged 18 years to 80 years Subject is scheduled for elective open or laparoscopic (including robotic) colon cancer resection surgery with primary anastomosis (excluding low anterior resection) Exclusion Criteria: Anastomosis is expected to be ≤ 10cm from anal verge Surgery involves stoma creation Subject who underwent a prior pelvic radiation therapy Subject with a BMI > 40 or <19 Subject with ASA status higher than 3 Albumin level < 3 gr/dl Total bilirubin >1.5 mg/dL Hemoglobin level < 8mg/dl on day of surgery Subject has a diagnosis of bowel strangulation, peritonitis, bowel perforation, local or systemic infection, ischemic bowel, and carcinomatosis Subject treated with immunosuppressive agents within 28 days prior to study enrollment (including corticosteroids) Serious or uncontrolled co-existent diseases (e.g. severe cardiovascular disease, congestive heart failure, recent myocardial infarction within 6 months from surgery, significant vascular disease, active or uncontrolled autoimmune disease, active or uncontrolled infection, uncontrolled DM with episodes of hospitalization due to hypo or hyperglycemia within 6 months of surgery) Subject known to have distant metastases, such as liver, lung, bone etc. metastases (not including local and regional lymph nodes) Subject with known sensitivity to Indigo carmine dye (FD&C 2/ E132) Subject who according to the investigator clinical judgement is not suitable for participation in the study or is at risk Subject requires more than one anastomosis during the surgery Subject is scheduled for another surgery during the follow up period of this study Subjects who cannot comply with study visits/ procedures or have poor compliance (e.g. mentally handicapped, prisoners, etc.) Intraoperative Exclusion Criteria: Subjects who meet any of the following intra-operative exclusion criteria will be considered as screen failures and will not be eligible for the study: Positive leak test requires anastomosis takedown and/or re-anastomosis. Additional resection (not including tissue biopsy) of non-colonic solid organ (e.g. Liver resection, uterus, bladder, seminal vesicle, ureter) Subjects whom anastomosis is ≤10 cm from the anal verge Subject received intraoperative sealant, glue or any buttressing material for the study related anastomosis, other than the Seal-G/Seal-G MIST Subject received two or more units of PC transfusion during surgery Subject has peritoneal carcinomatosis or any other metastasis observed by the surgeon
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Naama Giwnewer
Phone
+972.4.8291033
Email
naamag@admedsol.co.il
First Name & Middle Initial & Last Name or Official Title & Degree
Susan Clark
Email
susan.clark@admedsol.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Moshe Kamar, MD
Organizational Affiliation
Advanced Medical Solutions Israel (Sealantis) Ltd.
Official's Role
Study Director
Facility Information:
Facility Name
Sheba Medical Center (Tel Hashomer)
City
Ramat Gan
Country
Israel
Individual Site Status
Recruiting
Facility Name
Shamir (Assaf Harofeh) Medical Center
City
Rishon LeZion
Country
Israel
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Seal-G / Seal-G MIST Study

We'll reach out to this number within 24 hrs